Story
BlossomHill Therapeutics Shares Fall in Trading Debut After $150 Million IPO

Shares of BlossomHill Therapeutics Inc. (NASDAQ: BLSM) declined in their public market debut on Friday, a day after the oncology-focused biotechnology firm raised $150 million in an upsized initial public offering. The stock's performance indicates a muted reception from investors for the newly listed company.
Market Performance
BlossomHill's stock opened for trading in New York at $15.75, below its IPO price of $16.00 per share. According to Investing.com, the shares ended their first session down 1.6%.
Based on the number of outstanding shares listed in its filings, the trading gives the San Diego-based clinical-stage biopharmaceutical company a market valuation of approximately $482.6 million.
Offering Details
AdThe company priced its IPO on Thursday, selling 9,375,000 shares of common stock. This was an increase from the 7.8 million shares it had initially marketed at a price range of $15 to $17 each.
The offering generated gross proceeds of $150 million, before deducting underwriting discounts and other expenses. The deal's underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the public offering price. The offering is expected to close on August 10, 2026, subject to customary closing conditions.
J.P. Morgan, Leerink Partners, and Guggenheim Securities acted as lead book-running managers for the offering, with LifeSci Capital and H.C. Wainwright & Co. serving as joint book-running managers.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.